Luigino Nascimben, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Perioperative Period | 3 | 2019 | 256 | 0.770 |
Why?
|
| Cross Infection | 1 | 2019 | 1413 | 0.370 |
Why?
|
| Guideline Adherence | 1 | 2019 | 2266 | 0.340 |
Why?
|
| Creatine Kinase | 9 | 1997 | 694 | 0.330 |
Why?
|
| Quality Improvement | 2 | 2019 | 3738 | 0.290 |
Why?
|
| Heart Aneurysm | 1 | 2002 | 120 | 0.210 |
Why?
|
| Hospital Rapid Response Team | 1 | 2022 | 57 | 0.200 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2004 | 859 | 0.190 |
Why?
|
| Glycolysis | 1 | 2004 | 825 | 0.190 |
Why?
|
| Mitral Valve | 2 | 2013 | 1484 | 0.180 |
Why?
|
| Internship and Residency | 1 | 2019 | 5774 | 0.170 |
Why?
|
| Cardiac Output, Low | 2 | 1996 | 193 | 0.170 |
Why?
|
| Airway Management | 1 | 2022 | 324 | 0.160 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2013 | 1129 | 0.150 |
Why?
|
| Myocardium | 7 | 1996 | 4775 | 0.150 |
Why?
|
| Reminder Systems | 1 | 2019 | 370 | 0.140 |
Why?
|
| Problem-Based Learning | 1 | 2019 | 359 | 0.140 |
Why?
|
| Feedback | 1 | 2019 | 793 | 0.140 |
Why?
|
| Enalapril | 1 | 1995 | 327 | 0.110 |
Why?
|
| Kyphoplasty | 1 | 2013 | 44 | 0.110 |
Why?
|
| Aortic Valve | 1 | 2002 | 1911 | 0.110 |
Why?
|
| Polymethyl Methacrylate | 1 | 2013 | 145 | 0.100 |
Why?
|
| Coronary Artery Bypass | 2 | 2013 | 2281 | 0.100 |
Why?
|
| Fractures, Compression | 1 | 2013 | 134 | 0.100 |
Why?
|
| Bone Cements | 1 | 2013 | 325 | 0.100 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2013 | 1415 | 0.090 |
Why?
|
| Anesthesiology | 1 | 2019 | 1043 | 0.090 |
Why?
|
| Mandibular Diseases | 1 | 2010 | 119 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 1679 | 0.080 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2009 | 214 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2022 | 3203 | 0.080 |
Why?
|
| Intubation, Intratracheal | 2 | 2022 | 1357 | 0.080 |
Why?
|
| Osteonecrosis | 1 | 2010 | 227 | 0.080 |
Why?
|
| Heart Ventricles | 5 | 2013 | 3801 | 0.070 |
Why?
|
| Cardiomegaly | 2 | 2004 | 619 | 0.070 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 1573 | 0.060 |
Why?
|
| Phosphofructokinases | 1 | 2004 | 7 | 0.060 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2004 | 15 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 1538 | 0.060 |
Why?
|
| Aortitis | 1 | 2005 | 73 | 0.060 |
Why?
|
| Heart Failure | 3 | 2013 | 10856 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2010 | 814 | 0.060 |
Why?
|
| Troponin I | 1 | 2009 | 619 | 0.060 |
Why?
|
| Hypertension, Renovascular | 3 | 1989 | 123 | 0.060 |
Why?
|
| Laryngoscopy | 1 | 2010 | 706 | 0.060 |
Why?
|
| Mitral Valve Prolapse | 1 | 2006 | 230 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2004 | 424 | 0.060 |
Why?
|
| Isoenzymes | 4 | 1996 | 1725 | 0.060 |
Why?
|
| DNA Replication | 1 | 2010 | 1397 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2014 | 1873 | 0.050 |
Why?
|
| Rats, Wistar | 2 | 2004 | 1902 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 1997 | 3760 | 0.050 |
Why?
|
| Myocardial Contraction | 3 | 1996 | 1585 | 0.050 |
Why?
|
| Anesthesia Department, Hospital | 1 | 2022 | 68 | 0.050 |
Why?
|
| Prospective Payment System | 1 | 2022 | 133 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2004 | 608 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 686 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2013 | 15244 | 0.050 |
Why?
|
| Mesocricetus | 3 | 1996 | 251 | 0.050 |
Why?
|
| Aortic Aneurysm | 1 | 2005 | 643 | 0.050 |
Why?
|
| Energy Metabolism | 3 | 1996 | 2896 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2013 | 2370 | 0.050 |
Why?
|
| Personnel, Hospital | 1 | 2022 | 283 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 1869 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2013 | 3526 | 0.040 |
Why?
|
| Xenon Isotopes | 1 | 1997 | 65 | 0.040 |
Why?
|
| Xenon Radioisotopes | 1 | 1996 | 34 | 0.040 |
Why?
|
| Myosins | 2 | 1989 | 409 | 0.040 |
Why?
|
| Cricetinae | 3 | 1996 | 2471 | 0.040 |
Why?
|
| Mitochondria | 1 | 2010 | 3520 | 0.040 |
Why?
|
| Ventricular Dysfunction | 1 | 1997 | 143 | 0.040 |
Why?
|
| Adenosine Diphosphate | 1 | 1997 | 425 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 7153 | 0.030 |
Why?
|
| Myocardial Infarction | 3 | 2009 | 11690 | 0.030 |
Why?
|
| Electrocardiography | 3 | 2009 | 6440 | 0.030 |
Why?
|
| Blood | 1 | 1997 | 598 | 0.030 |
Why?
|
| Rats | 6 | 2004 | 24265 | 0.030 |
Why?
|
| Hospitalization | 1 | 2013 | 10232 | 0.030 |
Why?
|
| Phosphocreatine | 1 | 1993 | 269 | 0.030 |
Why?
|
| Texas | 1 | 2013 | 392 | 0.030 |
Why?
|
| Glucose | 1 | 2004 | 4391 | 0.030 |
Why?
|
| Captopril | 2 | 1989 | 272 | 0.030 |
Why?
|
| Reference Values | 2 | 1996 | 4982 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1996 | 2335 | 0.030 |
Why?
|
| Humans | 17 | 2022 | 742088 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 18006 | 0.030 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2013 | 194 | 0.030 |
Why?
|
| Systole | 1 | 2013 | 956 | 0.020 |
Why?
|
| Kinetics | 2 | 1996 | 6474 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 1914 | 0.020 |
Why?
|
| Mouthwashes | 1 | 2010 | 59 | 0.020 |
Why?
|
| Organ Size | 1 | 1995 | 2253 | 0.020 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1996 | 851 | 0.020 |
Why?
|
| Chest Tubes | 1 | 2010 | 150 | 0.020 |
Why?
|
| Clinical Enzyme Tests | 1 | 2009 | 115 | 0.020 |
Why?
|
| Turkeys | 3 | 1996 | 48 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2013 | 604 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2010 | 250 | 0.020 |
Why?
|
| Aged | 9 | 2013 | 162944 | 0.020 |
Why?
|
| Angiography | 1 | 2013 | 1636 | 0.020 |
Why?
|
| Tissue Donors | 1 | 1996 | 2205 | 0.020 |
Why?
|
| Male | 13 | 2013 | 349538 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 822 | 0.020 |
Why?
|
| Animals | 10 | 2004 | 168561 | 0.020 |
Why?
|
| Adenosine Triphosphate | 3 | 1997 | 2024 | 0.020 |
Why?
|
| Female | 10 | 2013 | 379592 | 0.020 |
Why?
|
| Body Weight | 1 | 1995 | 4664 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 1996 | 1912 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 1364 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2013 | 1844 | 0.010 |
Why?
|
| Rats, Inbred Strains | 3 | 1989 | 2191 | 0.010 |
Why?
|
| Middle Aged | 7 | 2013 | 213127 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 3001 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 1092 | 0.010 |
Why?
|
| Hospitals | 1 | 2014 | 3937 | 0.010 |
Why?
|
| Adult | 4 | 2010 | 213712 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9305 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2013 | 10248 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2010 | 3418 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2010 | 1638 | 0.010 |
Why?
|
| Time Factors | 3 | 2010 | 40054 | 0.010 |
Why?
|
| Wound Healing | 1 | 2010 | 2781 | 0.010 |
Why?
|
| Radiography | 1 | 2010 | 7010 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12344 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 39004 | 0.010 |
Why?
|
| Antimetabolites | 1 | 1997 | 125 | 0.010 |
Why?
|
| Furazolidone | 1 | 1996 | 5 | 0.010 |
Why?
|
| Deoxyglucose | 1 | 1997 | 337 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 1997 | 199 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1997 | 324 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1989 | 1801 | 0.010 |
Why?
|
| Length of Stay | 1 | 2009 | 6294 | 0.010 |
Why?
|
| Erythrocyte Membrane | 1 | 1997 | 442 | 0.010 |
Why?
|
| Propionates | 1 | 1996 | 168 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2013 | 53187 | 0.010 |
Why?
|
| Guanidines | 1 | 1996 | 191 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2013 | 62966 | 0.010 |
Why?
|
| Diastole | 1 | 1997 | 791 | 0.010 |
Why?
|
| Creatine | 1 | 1996 | 421 | 0.010 |
Why?
|
| United States | 1 | 2022 | 69693 | 0.010 |
Why?
|
| Iodoacetamide | 1 | 1993 | 35 | 0.010 |
Why?
|
| Heparin | 1 | 1981 | 1636 | 0.010 |
Why?
|
| Phosphorus | 1 | 1993 | 338 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 12773 | 0.010 |
Why?
|
| Cattle | 1 | 1997 | 3923 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1997 | 1532 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2010 | 12164 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20086 | 0.010 |
Why?
|
| Phosphates | 1 | 1993 | 786 | 0.010 |
Why?
|
| Adolescent | 1 | 1996 | 85649 | 0.010 |
Why?
|
| Models, Neurological | 1 | 1996 | 1771 | 0.000 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1987 | 123 | 0.000 |
Why?
|
| Peptide Mapping | 1 | 1987 | 263 | 0.000 |
Why?
|
| Hypertension | 1 | 1987 | 8455 | 0.000 |
Why?
|
| Risk Factors | 1 | 2013 | 72145 | 0.000 |
Why?
|
| Oxygen | 1 | 1997 | 4169 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1989 | 1372 | 0.000 |
Why?
|
| Remission Induction | 1 | 1989 | 2384 | 0.000 |
Why?
|
| Young Adult | 1 | 2010 | 56350 | 0.000 |
Why?
|
| Calcium | 1 | 1996 | 5753 | 0.000 |
Why?
|
| Heart | 1 | 1996 | 4462 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 8300 | 0.000 |
Why?
|
| Nitro Compounds | 1 | 1981 | 75 | 0.000 |
Why?
|
| Digoxin | 1 | 1981 | 250 | 0.000 |
Why?
|
| Age Factors | 1 | 1996 | 18355 | 0.000 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1981 | 363 | 0.000 |
Why?
|
| Diuretics | 1 | 1981 | 591 | 0.000 |
Why?
|
| Models, Biological | 1 | 1993 | 9581 | 0.000 |
Why?
|
| Brain | 1 | 1996 | 26343 | 0.000 |
Why?
|
| Aspirin | 1 | 1981 | 3278 | 0.000 |
Why?
|